Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Departamentos, Grupos de Investigación e Institutos >
Departamento de Bioquímica y Biología Molecular I >
DBBM1 - Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/37314

Title: Prognosis Relevance of Serum Cytokines in Pancreatic Cancer
Authors: Torres, Carolina
Linares Gil, Ana
Alejandre Pérez, María José
Palomino Morales, Rogelio
Caba Pérez, Octavio
Prados, José
Aránega Jiménez, Antonia
Delgado Pérez, Juan Ramón
Irigoyen, Antonio
Martínez-Galán, Joaquina
Ortuño, Francisco M.
Rojas Ruiz, Ignacio
Perales Romero, Sonia
Issue Date: 2015
Abstract: The overall survival of patients with pancreatic ductal adenocarcinoma is extremely low. Although gemcitabine is the standard used chemotherapy for this disease, clinical outcomes do not reflect significant improvements, not even when combined with adjuvant treatments. There is an urgent need for prognosis markers to be found. The aim of this study was to analyze the potential value of serum cytokines to find a profile that can predict the clinical outcome in patients with pancreatic cancer and to establish a practical prognosis index that significantly predicts patients’ outcomes. We have conducted an extensive analysis of serum prognosis biomarkers using an antibody array comprising 507 human cytokines. Overall survival was estimated using the Kaplan-Meier method. Univariate and multivariate Cox’s proportional hazard models were used to analyze prognosis factors. To determine the extent that survival could be predicted based on this index, we used the leave-one-out cross-validation model. The multivariate model showed a better performance and it could represent a novel panel of serum cytokines that correlates to poor prognosis in pancreatic cancer. B7-1/CD80, EG-VEGF/PK1, IL-29, NRG1-beta1/HRG1-beta1, and PD-ECGF expressions portend a poor prognosis for patients with pancreatic cancer and these cytokines could represent novel therapeutic targets for this disease.
Sponsorship: The study was fully supported by ROCHE FARMA S.A (ref. H/OH-TAR-10/131 and ref. H/OH-TRR-08/59) and Instituto de Salud Carlos III (ISCIII) (Clinical trial ref. EC08/00009), and the Government of Andalusia Project P12-TIC-2082.
Publisher: Hindawi Publishing Corporation
Keywords: Serum cytokines
Pancreatic cancer
Chemotherapy
Markers
Pancreatic ductal adenocarcinoma
URI: http://hdl.handle.net/10481/37314
ISSN: 2314-6133
2314-6141
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Citation: Torres, C.; et al. Prognosis Relevance of Serum Cytokines in Pancreatic Cancer. Biomed Research International, 2015: 518284 (2015). [http://hdl.handle.net/10481/37314]
Appears in Collections:DBBM1 - Artículos

Files in This Item:

File Description SizeFormat
Torres_PancreaticCancer.pdf1.49 MBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada